ENRIQUETA FELIP

Has grant

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Enriqueta Felip is the Head of the Thoracic Oncology Unit at Hospital Vall d'Hebron in Spain. Her research primarily focuses on advancements in lung cancer treatment, evidenced by her recent publications on topics such as small cell lung cancer, non-small cell lung cancer, and various therapeutic agents. She has contributed significantly to the understanding of clinical outcomes related to novel immunotherapies and targeted treatments in oncology.

Recent Grants

Grant: Close

ESMO Women for Oncology Award

Open Date: 2015-09-01

Close Date:

Grant: Close

"Next generation molecular platforms to identify new therapeutics targets and prognostic markers neglected types of lung cancer".

Open Date: 2014-11-01

Close Date: 2019-10-01

Grant: Close

"SPECTAlung: Screening Patients with Thoracic tumors for Efficient Clinical Trial Access"

Open Date: 2014-01-01

Close Date: 2018-01-01

Grant: Close

BARCELONA OFFCIAL SCHOOL OF MEDICINE "Professional Excellence Award"

Open Date: 2012-11-01

Close Date:

Grant: Close

"Dr. Robert Ginsberg Award Lectureship in Surgery 2009 to Enriqueta Felip" (IASLC)

Open Date: 2009-07-01

Close Date:

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (14)

Manel Juan

Head of Immunology service/department

Hospital Clínic de Barcelona

SPAIN

View details

Suresh Ramalingam

Professor, Director of Medical Oncology

Emory University

UNITED STATES

View details

Marina Garassino

Università degli Studi di Torino

ITALY

View details

Benjamin Besse

Université Paris-Saclay

FRANCE

View details

Olatunji B. Alese

UNITED STATES

View details

Nathan Pennell

Associate Professor

Cleveland Clinic

UNITED STATES

View details

Ana Arance

University of Barcelona

SPAIN

View details

Jordi Canes

Scientific Manager Head

SPAIN

View details

Takayuki Takahama

Lecturer

Kindai University Hospital

JAPAN

View details

Francesco Gelsomino

ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA

ITALY

View details

JULIEN MAZIERES

PROFESSOR

FRANCE

View details

Muhammad Furqan

Associate Professor

University of Iowa Healthcare

UNITED STATES

View details

Dong-Wan Kim

Associate Professor

Seoul National University Hospital

SOUTH KOREA

View details

Xavier Gonzàlez Farré

Associate professor

Universitat Internacional de Catalunya

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ENRIQUETA FELIP

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors

Safety and Tolerability of Lete-cel in NSCLC—Reply

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC

TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of <i>PD1</i> mRNA

Collaborators (14)

Manel Juan

Suresh Ramalingam

Marina Garassino

Benjamin Besse

Olatunji B. Alese

Nathan Pennell

Ana Arance

Jordi Canes

Takayuki Takahama

Francesco Gelsomino

JULIEN MAZIERES

Muhammad Furqan

Dong-Wan Kim

Xavier Gonzàlez Farré

Make your next move.